Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma

NCT04936841 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped study closed by the sponsor

Conditions

Head and Neck Cancer

Interventions

DRUG: NKTR-214
DRUG: anti-PD-1 therapy
RADIATION: Palliative Radiation

Sponsor

University of Wisconsin, Madison

Collaborators

[object Object]